Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • No Relief: DOP rejects...

    No Relief: DOP rejects review petition by CIPLA challenging NPPA price fixation

    Farhat NasimWritten by Farhat Nasim Published On 2020-01-12T10:00:03+05:30  |  Updated On 12 Jan 2020 10:00 AM IST

    New Delhi: Holding that drugmaker, Cipla did not comply with the mandatory implementation of the retail price of the formulation before filing the review petition, the Department of Pharmaceuticals (DoP) has rejected the review petition filed by the drugmaker against the apex drug price regulator, National Pharmaceutical Pricing Authority (NPPA) for fixing the retail price of their formulation “Formoteraol Fumarate Dihydrate 6mcg + Beclomethasone Dipropionate IP 100MCG Inhaler (MDI)”.


    Medical Dialogues had earlier reported that NPPA had fixed the retail price of 10 drug formulations under the Drugs Prices Control Order (DPCO), 2013, exclusive of goods and services tax (GST) including Cipla's said formulation at Rs 1.46 for per metered dose.


    Also Read: NPPA fixes the retail price of 10 combo drugs including Metformin, Rosuvastatin; Details

    Thereafter, Cipla moved an application to review the price of its Inhaler fixed by NPPA. However, it was noted by the DoP that the company has launched the product without complying with the notified price.


    As per Para 31 of DPCO, 2013, it is mandatory for the applicant company to implement the ceiling/retail price of the formulation before filing the review petition. Para 31 of DPCO, 2013 states ;


    “……pending a decision by the Government on the application submitted under the above paragraph, no manufacturer shall sell a scheduled formulation or a new drug, as the case may be, at a price exceeding the ceiling price or retail price, as the case may be, fixed by the Government of which a review has been applied for.”


    Noting the same, the Department held;

    "The product Formoterol Fumarate Dihydrate 6mcg + Beclomethasone Dipropionate 100 mcg inhaler (MDI) has been launched by the company without complying with the price notified vide SO 2944(E), dated 14.08.2019. Hence, as per provisions contained in para 31 of DPCO, the review application dated 11.09.2019 stands rejected."



    Also Read: NPPA fixes price of Cipla Synchrobreathe inhaler device; Details
    Beclomethasone DipropionateCiplaDept of pharmaDOPDPCODrug (Price Control) Orderdrug priceFormoteraol Fumarate DihydrateinhalerNational Pharmaceuticals Pricing AuthorityNPPApharmapharma newsretail pricereview petition

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok